Percutaneous left atrial appendage occlusion in a frail, high-risk, octogenarian patient population, after having undergone transcatheter aortic valve implantation

BMC Cardiovasc Disord. 2022 Aug 2;22(1):349. doi: 10.1186/s12872-022-02786-4.

Abstract

Background: Percutaneous left atrial appendage occlusion (LAAO) represents an alternative stroke prevention method in patients with atrial fibrillation and an increased bleeding risk, chronic kidney disease or contraindications to oral anticoagulants. Aim of our study was to evaluate the feasibility and safety of percutaneous LAAO in high-risk, frail patients having undergone transcatheter aortic valve implantation (TAVI).

Methods: Thirty-one patients having undergone TAVI and scheduled for LAAO were prospectively included in our study.

Results: Implantation was successful in 29 of 31 cases (93.5%).There were no patients that developed a major acute cardiovascular event, stroke, or device dislocation/embolization. There was a single case of major bleeding (3.2%) and 3 cases of acute kidney injury (9.7%). At 3 months, no patients experienced a stroke, one patient had a device-related thrombus (3.4%), one patient showed a significant peri-device leak, and one patient had a persistent iatrogenic atrial septal defect.

Conclusions: Our study shows that percutaneous LAAO may represent a feasible alternative strategy for stroke prevention, that can be safely performed in high-risk, multimorbid patients with high bleeding risk or contraindications to oral anticoagulation.

Keywords: Atrial fibrillation; Bleeding risk; Elderly; Frail; Left atrial appendage occlusion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticoagulants / adverse effects
  • Atrial Appendage* / diagnostic imaging
  • Atrial Appendage* / surgery
  • Atrial Fibrillation* / surgery
  • Atrial Fibrillation* / therapy
  • Frail Elderly
  • Humans
  • Octogenarians
  • Septal Occluder Device*
  • Stroke* / etiology
  • Stroke* / prevention & control
  • Transcatheter Aortic Valve Replacement* / adverse effects
  • Treatment Outcome

Substances

  • Anticoagulants